Evelo Biosciences Inc (EVLO)
Evelo Biosciences, Inc. is a clinical-stage biotechnology company focused on developing oral medicines designed to interact with immune cells in the small intestine and produce systemic effects. Its pipeline includes EDP1815, a whole-microbe candidate that has completed a Phase 2 study in psoriasis, as well as EDP1867, a non-live preparation based on a single strain of Veillonella parvula that is in Phase 1b testing. The company is also advancing EDP2939, an oral biologic being studied for inflammatory diseases, and EDP1908, a candidate under development for oncology. Evelo Biosciences was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The listed security is common stock on OTC Markets.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-EVLO
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
0.018 K
|